Chiasma, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Chiasma, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies for rare and serious chronic diseases. The company specializes in oral delivery of peptide drugs using its proprietary Transient Permeability Enhancer (TPE) technology platform, which enables the conversion of injectable drugs into oral formulations. Its main product is MYCAPSSA (octreotide capsules), the first and only FDA-approved oral somatostatin analog used for the maintenance treatment of adult patients with acromegaly who have responded to prior injectable somatostatin analogs. Chiasma targets patients with rare endocrine disorders and operates primarily in the United States. Founded in 2001 and headquartered in Needham, Massachusetts, the company focuses on rare disease therapies and patient-centric drug delivery solutions. In recent major developments, Chiasma was acquired by Amryt Pharma plc in May 2021, an acquisition that expanded its global footprint and pipeline within the rare and orphan disease sector. Post-acquisition, Chiasma leverages Amryt Pharma’s resources to enhance commercialization capabilities and pipeline development, aiming to strengthen its leadership in oral therapies for rare diseases. The company recently secured non-dilutive financing agreements to support the ongoing commercialization and launch efforts of MYCAPSSA in the U.S. market. Chiasma continues its efforts to broaden the application of its TPE technology to develop additional oral peptide therapies, reinforcing its strategic shift towards organic growth and internal development within the biopharmaceutical industry focused on rare chronic conditions.
Amryt Pharma completes Chiasma acquisition
INVESTIGATION ALERT: Halper Sadeh LLP Investigates ONEM, SYKE, NETE, CHMA, SOLY, ARPO; Shareholders are Encouraged to Contact the Firm
Chiasma Files Mycapssa European Application For Acromegaly
Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines Agency
Chiasma's Mycapssa Associated With Positive Patient-Reported Outcomes In Acromegaly Patients
Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm
Chiasma (CHMA) is Overbought: Is A Drop Coming?
Amryt Pharma plc (AMYT) Amryt Pharma Acquisition of Chiasma Inc. and Q1 2021 Earnings Conference (Transcript)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Chiasma, Inc. - CHMA
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Chiasma, Inc.
Why Chiasma's Stock Is Surging Today
Chiasma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Chiasma, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CHMA
Hot Penny Stocks to Buy? 3 to Watch on Cinco De Mayo
CHMA Stock: From $2.84 To $4.07 (43.31% Increase) Pre-Market Explanation
Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt
CHMA Stock Price Increases Over 10% Pre-Market: Why It Happened
Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021
Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021